1. Four guidelines on cardiovascular complications and cardiovascular disease, prognosis and treatment in COVID‑19

   • H. J. Siebelink
   • C. W. Jansen
   • J. Hoogervorst-Schilp

   Introduction Open access 15 April 2021 Pages: 2 - 4

2. How often and to what extent do admitted COVID-19 patients have signs of cardiac injury?

   • M. A. W. Habets
   • H. N. Sturkenboom
   • P. C. Smits

   Guideline Open access 16 April 2021 Pages: 5 - 12

   

3. Impact of cardiovascular disease and cardiovascular risk factors in hospitalised COVID-19 patients

   • L. S. D. Jewbali
   • J. Hoogervorst-Schilp
   • H. J. Siebelink

   Guideline Open access 16 April 2021 Pages: 13 - 19

4. The effects of ACE2 expression mediating pharmacotherapy in COVID-19 patients

   • R. R. J. van Kimmenade
   • E. Belfroid
   • Y. Pinto

   Guideline Open access 16 April 2021 Pages: 20 - 34

   

5. Effect of anticoagulant therapy in COVID-19 patients

   • R. G. Tieleman
   • F. A. Klok
   • H. J. Siebelink

   Guideline Open access 16 April 2021 Pages: 35 - 44